As part of movement to boost African presence, Grifols to build IV bag facility in Nigeria
In an effort to curb supply chain shortages and enable local governments to be more self-reliant, Grifols has announced its second expansion into Africa in the past year.
Grifols will construct an intravenous solutions plant in Nigeria for Dozie and Dozie’s Pharma, a Nigerian company formed to establish specialty medicines for oncology and immunology, among others.
The plant is set to be up and running by 2024, and will produce 5.5 million IV bags a year for the company.
The move is aimed at helping the region become more self-sufficient with its pharmaceuticals. Grifols upped its presence in Africa in November 2020 when it entered an alliance with Egypt’s government to open 20 plasma centers and construct plasma fractionation and pill-finish plants.
The pact allowed Grifols to establish a presence in the Middle East as well and allowed the two parties to join forces to have enough capacity to collect 600,000 liters of plasma a year, and a fractionation capacity of up to 1 million liters per year. That project will be carried out over the course of five years, and was projected to cost roughly $300 million.
It also has established a plasma collection center and modular labs in Liberia in an effort to curb Ebola, as well as an IV solutions plant in Morocco.
“This plant is the latest demonstration of our ongoing commitment to provide high-quality medicines and healthcare solutions to meet the growing needs of the region,” Dozie and Dozie CEO Chidi Dozie said.